Sponsored by Astrea BioSeparations and Benchling, Drug Discovery World has published this guide, the first of a new guide series, entitled “Where is the global innovation and the opportunity in cell and gene therapy?”.
Natalia and Naiara share their thoughts in the “Expert views on the challenges and opportunities for cell and gene therapies in 2023” chapter, in which they say they anticipate “2023 will be a very good year for VIVEbiotech, due to the increasing demand for lentiviral vectors”. They continue saying that the gene therapy market in general, and the lentiviruses market by association, is growing enormously. Natalia and Naiara believe that “as with any other sector, in gene therapy there are also threats that must be closely watched. But given that viral vectors are today the most efficient vehicle for successfully delivering healthy genes to diseased cells, we believe 2023 will be a promising year for viral vector manufacturers.”
Thank you very much to Astrea BioSeparations and Benchling for sponsoring the guide, and to Drug Discovery World for spreading the word.
You can download this free, exclusive guide, here: https://www.ddw-online.com/latest-ddw-guide-exclusive-insight-into-cell-gene-therapy-innovation-and-opportunity-21551-202301/